IAM interviews Sarah Spires about TwinStrand Biosciences’ $245M judgment against Guardant Health

Partner Sarah Spires was featured today in an IAM article titled “TwinStrand’s $245M win signals growing value of biotech patent monetisation.”

The article highlights TwinStrand’s victory against Guardant as evidence of a shift in biotech funding, where smaller companies are increasingly turning to licensing and patent monetization as a revenue stream.

Spires observes that biotech companies used to avoid monetizing unused patents, as the industry viewed such moves with a “taboo label.” That stigma is now fading. “We’re absolutely seeing [licensing] explode in the last few years,” she says, and biotech IP is starting to function like a financial asset class.

Read the full IAM article here (subscription required).